Discover
VNRX
VolitionRx Limited
1.36
300 x undefined
7000 x undefined
bid
ask
+
0.01
0.74%
3650 @ 05:18 AM
1.39 +0.03 (2.21%)
| Ytd | -73.85% | |
| 1y | -91.17% |
1.33
day range
1.41
1.17
52 week range
16.40
| Open | 1.36 | Prev Close | 1.35 | Low | 1.33 | High | 1.41 | Mkt Cap | 16.21M |
| Vol | 200.81K | Avg Vol | 285.36K | EPS | -4.25 | P/E | N/A | Forward P/E | -3.83 |
| Beta | 1.10 | Short Ratio | 3.71 | Inst. Own | 19.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.13 | 200-d Avg | 5.40 | 1yr Est | 3.34 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.07 | -0.07 | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.09 | -0.08 | 0.01 | 11.11% |
| 2024-05-13 | 2024-03 | -0.11 | -0.1 | 0.01 | 9.09% |
| 2024-03-25 | 2023-12 | 0 | -0.11 | N/A | N/A |
| 2023-11-14 | 2023-09 | -0.12 | -0.11 | 0.01 | 8.33% |
| 2023-08-14 | 2023-06 | -0.13 | -0.14 | -0.01 | -7.69% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-10 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-11-22 | Benchmark | Upgrade | Hold | |
| 2024-11-15 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-11-01 | EF Hutton | Upgrade | Buy | Buy |
| 2024-08-16 | Benchmark | Upgrade | Hold | |
| 2024-06-07 | EF Hutton | Upgrade | Buy | Buy |
Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-28 | BUTERA SALVATORE THOMAS | Officer | 392.94K | Stock Award(Grant) |
| 2024-11-28 | COLMAN ALAN | Director | 230.52K | Stock Award(Grant) |
| 2024-11-28 | FORTERRE GAEL | Officer | 194.68K | Stock Award(Grant) |
| 2024-11-28 | HUGHES TERIG | Chief Financial Officer | 376.25K | Stock Award(Grant) |
| 2024-12-08 | INNES GUY ARCHIBALD | Director | 2.99M | Purchase |
| 2024-11-28 | KWAY JASMINE | Officer | 176.47K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 9.00M | 5.52M | 9.71% |
| 2024-09-29 | Lagoda Investment Management, L.P. | 6.10M | 3.74M | 6.58% |
| 2024-09-29 | Geode Capital Management, LLC | 730.45K | 447.84K | 0.79% |
| 2024-09-29 | Vanguard Group Inc | 636.67K | 390.34K | 0.69% |
| 2024-09-29 | Blackrock Inc. | 445.19K | 272.94K | 0.48% |
| 2024-09-29 | Silverberg Bernstein Capital Management LLC | 142.62K | 87.44K | 0.15% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Extended Market Index Fund | 622.95K | 381.93K | 0.67% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 409.15K | 250.85K | 0.44% |
| 2024-10-30 | Fidelity Total Market Index Fund | 142.51K | 87.37K | 0.15% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 96.68K | 59.27K | 0.10% |
| 2024-07-30 | Schwab Capital Trust-Total Stock Market Index Fund | 15.38K | 9.43K | 0.02% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 18.08K | 11.08K | 0.02% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2026-04-28 |